The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Metastatic Melanoma Drug-Global Market Insights and Sales Trends 2025

Metastatic Melanoma Drug-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1813434

No of Pages : 103

Ask Your Query
Synopsis
The global Metastatic Melanoma Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Metastatic Melanoma Drug in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Metastatic Melanoma Drug market. AGI-134, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ALT-801 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Metastatic Melanoma Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Metastatic Melanoma Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Metastatic Melanoma Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Metastatic Melanoma Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Metastatic Melanoma Drug covered in this report include Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc. and OncoSec Medical Inc., etc.
The global Metastatic Melanoma Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
Plexxikon Inc.
Global Metastatic Melanoma Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Metastatic Melanoma Drug market, Segment by Type:
AGI-134
ALT-801
ALT-803
AMG-232
Others
Global Metastatic Melanoma Drug market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Metastatic Melanoma Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Metastatic Melanoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Metastatic Melanoma Drug Market Overview
1.1 Metastatic Melanoma Drug Product Overview
1.2 Metastatic Melanoma Drug Market Segment by Type
1.2.1 AGI-134
1.2.2 ALT-801
1.2.3 ALT-803
1.2.4 AMG-232
1.2.5 Others
1.3 Global Metastatic Melanoma Drug Market Size by Type
1.3.1 Global Metastatic Melanoma Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Metastatic Melanoma Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Metastatic Melanoma Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Metastatic Melanoma Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Metastatic Melanoma Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Metastatic Melanoma Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Metastatic Melanoma Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Metastatic Melanoma Drug Sales Breakdown by Type (2018-2023)
2 Global Metastatic Melanoma Drug Market Competition by Company
2.1 Global Top Players by Metastatic Melanoma Drug Sales (2018-2023)
2.2 Global Top Players by Metastatic Melanoma Drug Revenue (2018-2023)
2.3 Global Top Players by Metastatic Melanoma Drug Price (2018-2023)
2.4 Global Top Manufacturers Metastatic Melanoma Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Metastatic Melanoma Drug Market Competitive Situation and Trends
2.5.1 Metastatic Melanoma Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Metastatic Melanoma Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Metastatic Melanoma Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Metastatic Melanoma Drug Market
2.8 Key Manufacturers Metastatic Melanoma Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Metastatic Melanoma Drug Status and Outlook by Region
3.1 Global Metastatic Melanoma Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Metastatic Melanoma Drug Historic Market Size by Region
3.2.1 Global Metastatic Melanoma Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Metastatic Melanoma Drug Sales in Value by Region (2018-2023)
3.2.3 Global Metastatic Melanoma Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Metastatic Melanoma Drug Forecasted Market Size by Region
3.3.1 Global Metastatic Melanoma Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Metastatic Melanoma Drug Sales in Value by Region (2024-2029)
3.3.3 Global Metastatic Melanoma Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Metastatic Melanoma Drug by Application
4.1 Metastatic Melanoma Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Metastatic Melanoma Drug Market Size by Application
4.2.1 Global Metastatic Melanoma Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Metastatic Melanoma Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Metastatic Melanoma Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Metastatic Melanoma Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Metastatic Melanoma Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Metastatic Melanoma Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Metastatic Melanoma Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Metastatic Melanoma Drug Sales Breakdown by Application (2018-2023)
5 North America Metastatic Melanoma Drug by Country
5.1 North America Metastatic Melanoma Drug Historic Market Size by Country
5.1.1 North America Metastatic Melanoma Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Metastatic Melanoma Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Metastatic Melanoma Drug Sales in Value by Country (2018-2023)
5.2 North America Metastatic Melanoma Drug Forecasted Market Size by Country
5.2.1 North America Metastatic Melanoma Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Metastatic Melanoma Drug Sales in Value by Country (2024-2029)
6 Europe Metastatic Melanoma Drug by Country
6.1 Europe Metastatic Melanoma Drug Historic Market Size by Country
6.1.1 Europe Metastatic Melanoma Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Metastatic Melanoma Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Metastatic Melanoma Drug Sales in Value by Country (2018-2023)
6.2 Europe Metastatic Melanoma Drug Forecasted Market Size by Country
6.2.1 Europe Metastatic Melanoma Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Metastatic Melanoma Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Metastatic Melanoma Drug by Region
7.1 Asia-Pacific Metastatic Melanoma Drug Historic Market Size by Region
7.1.1 Asia-Pacific Metastatic Melanoma Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Metastatic Melanoma Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Metastatic Melanoma Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Metastatic Melanoma Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Metastatic Melanoma Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Metastatic Melanoma Drug Sales in Value by Region (2024-2029)
8 Latin America Metastatic Melanoma Drug by Country
8.1 Latin America Metastatic Melanoma Drug Historic Market Size by Country
8.1.1 Latin America Metastatic Melanoma Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Metastatic Melanoma Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Metastatic Melanoma Drug Sales in Value by Country (2018-2023)
8.2 Latin America Metastatic Melanoma Drug Forecasted Market Size by Country
8.2.1 Latin America Metastatic Melanoma Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Metastatic Melanoma Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Metastatic Melanoma Drug by Country
9.1 Middle East and Africa Metastatic Melanoma Drug Historic Market Size by Country
9.1.1 Middle East and Africa Metastatic Melanoma Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Metastatic Melanoma Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Metastatic Melanoma Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Metastatic Melanoma Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Metastatic Melanoma Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Metastatic Melanoma Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Merck & Co., Inc.
10.1.1 Merck & Co., Inc. Company Information
10.1.2 Merck & Co., Inc. Introduction and Business Overview
10.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Products Offered
10.1.5 Merck & Co., Inc. Recent Development
10.2 Merck KGaA
10.2.1 Merck KGaA Company Information
10.2.2 Merck KGaA Introduction and Business Overview
10.2.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Merck KGaA Metastatic Melanoma Drug Products Offered
10.2.5 Merck KGaA Recent Development
10.3 Millennium Pharmaceuticals, Inc.
10.3.1 Millennium Pharmaceuticals, Inc. Company Information
10.3.2 Millennium Pharmaceuticals, Inc. Introduction and Business Overview
10.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Products Offered
10.3.5 Millennium Pharmaceuticals, Inc. Recent Development
10.4 Morphotek, Inc.
10.4.1 Morphotek, Inc. Company Information
10.4.2 Morphotek, Inc. Introduction and Business Overview
10.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Morphotek, Inc. Metastatic Melanoma Drug Products Offered
10.4.5 Morphotek, Inc. Recent Development
10.5 NewLink Genetics Corporation
10.5.1 NewLink Genetics Corporation Company Information
10.5.2 NewLink Genetics Corporation Introduction and Business Overview
10.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Products Offered
10.5.5 NewLink Genetics Corporation Recent Development
10.6 Novartis AG
10.6.1 Novartis AG Company Information
10.6.2 Novartis AG Introduction and Business Overview
10.6.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Novartis AG Metastatic Melanoma Drug Products Offered
10.6.5 Novartis AG Recent Development
10.7 Omeros Corporation
10.7.1 Omeros Corporation Company Information
10.7.2 Omeros Corporation Introduction and Business Overview
10.7.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Omeros Corporation Metastatic Melanoma Drug Products Offered
10.7.5 Omeros Corporation Recent Development
10.8 Oncolytics Biotech Inc.
10.8.1 Oncolytics Biotech Inc. Company Information
10.8.2 Oncolytics Biotech Inc. Introduction and Business Overview
10.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Products Offered
10.8.5 Oncolytics Biotech Inc. Recent Development
10.9 OncoSec Medical Inc.
10.9.1 OncoSec Medical Inc. Company Information
10.9.2 OncoSec Medical Inc. Introduction and Business Overview
10.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Products Offered
10.9.5 OncoSec Medical Inc. Recent Development
10.10 Ono Pharmaceutical Co., Ltd.
10.10.1 Ono Pharmaceutical Co., Ltd. Company Information
10.10.2 Ono Pharmaceutical Co., Ltd. Introduction and Business Overview
10.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Products Offered
10.10.5 Ono Pharmaceutical Co., Ltd. Recent Development
10.11 Pfizer Inc.
10.11.1 Pfizer Inc. Company Information
10.11.2 Pfizer Inc. Introduction and Business Overview
10.11.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Pfizer Inc. Metastatic Melanoma Drug Products Offered
10.11.5 Pfizer Inc. Recent Development
10.12 Pharmis Biofarmaceutica, Lda.
10.12.1 Pharmis Biofarmaceutica, Lda. Company Information
10.12.2 Pharmis Biofarmaceutica, Lda. Introduction and Business Overview
10.12.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Products Offered
10.12.5 Pharmis Biofarmaceutica, Lda. Recent Development
10.13 Philogen S.p.A.
10.13.1 Philogen S.p.A. Company Information
10.13.2 Philogen S.p.A. Introduction and Business Overview
10.13.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Philogen S.p.A. Metastatic Melanoma Drug Products Offered
10.13.5 Philogen S.p.A. Recent Development
10.14 Plexxikon Inc.
10.14.1 Plexxikon Inc. Company Information
10.14.2 Plexxikon Inc. Introduction and Business Overview
10.14.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Plexxikon Inc. Metastatic Melanoma Drug Products Offered
10.14.5 Plexxikon Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Metastatic Melanoma Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Metastatic Melanoma Drug Industrial Chain Analysis
11.4 Metastatic Melanoma Drug Market Dynamics
11.4.1 Metastatic Melanoma Drug Industry Trends
11.4.2 Metastatic Melanoma Drug Market Drivers
11.4.3 Metastatic Melanoma Drug Market Challenges
11.4.4 Metastatic Melanoma Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Metastatic Melanoma Drug Distributors
12.3 Metastatic Melanoma Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock